[Cost-Effectiveness Analysis of Maribavir in Patients With Post-Transplant Cytomegalovirus Infection or Disease That Are Refractory or Resistant to Conventional Therapy]. FE 2023, 24 (1). https://doi.org/10.7175/fe.v24i1.1548.